Inclusive Clinical Trials: An Oxymoron?

Why It Matters

If regulators push for broader trial enrollment, pharmaceutical sponsors could face higher costs, delayed timelines, and uncertain data quality, affecting drug approval and market launch strategies.

Key Takeaways

• Pivotal trials prioritize internal validity over demographic diversity.
• FDA has ~12 REMS for teratogenic drugs, despite 206 risks.
• Post‑marketing studies, not trial inclusion, better for pregnancy safety.
• Subgroup analyses often generate spurious hypotheses, not actionable data.
• Recruiting pregnant women adds complexity and error risk to trials.

Pulse Analysis

The call for more inclusive clinical trials has gained momentum as patient‑advocacy groups and some regulators argue that data should reflect real‑world populations. In theory, enrolling pregnant or lactating women could close knowledge gaps about drug safety during these critical periods. However, the operational realities of phase‑III studies—tight inclusion criteria, controlled environments, and the need for clear causal inference—make such expansion a logistical and methodological challenge. Sponsors must weigh the ethical imperative against the risk of diluting trial power and compromising the statistical robustness required for regulatory approval.

Scientific concerns extend beyond recruitment hurdles. Subgroup analyses, often used to tease out effects in specific populations, are notoriously prone to false‑positive findings. Historical examples, such as spurious links between zodiac signs and aspirin outcomes, illustrate how post‑hoc slicing can mislead clinicians and regulators alike. When it comes to pregnancy, the scarcity of reliable data is less about absence of studies and more about under‑utilization of existing evidence. The FDA’s modest portfolio of roughly twelve REMS for teratogenic agents, despite over 200 drugs flagged for fetal risk, underscores a systemic gap between risk identification and actionable mitigation.

A pragmatic alternative lies in robust post‑marketing surveillance. Real‑world evidence gathered from electronic health records, prescription databases, and targeted registries can provide the nuanced safety signals that pre‑approval trials cannot. Investing in such infrastructure not only aligns with regulatory expectations but also offers a cost‑effective route to generate actionable data without jeopardizing trial integrity. For pharmaceutical companies, embracing a dual strategy—maintaining rigorous, internally valid pivotal trials while committing resources to comprehensive post‑marketing studies—balances ethical responsibility with commercial viability.